Financials

2009, a year of execution and delivery

The company reached a turning point through new drug approvals and launches as well as the transformation of its organisation. UCB achieved major development and regulatory milestones and reduced and refinanced the existing debt with a new financing structure reflecting an improved maturity profile. With all this, UCB created a strong basis for sustainable future growth.

• Multiple approvals and launches: Cimzia® for RA in the U.S. and EU, Vimpat® for epilepsy in the U.S. and in the EU, Neupro® for new patients in Parkinson's disease and RLS in the EU
• Total revenue decreased as expected by 13% to € 3.1 billion due to the full-year impact of generic competition to Keppra® in the U.S. and divestitures
• Strong underlying profitability (recurring EBITDA) of
  € 698 million (-5%) well in line with company guidance (more than € 680 million) and reflecting the significant impact of generic competition to Keppra® in the U.S., mostly compensated by lower operating expenses as a result of UCB's focus on its core activities
• Net profit after minorities increased to € 513 million in 2009 from € 42 million in 2008, reflecting higher non-recurring income stemming from capital gains and overcompensating non-recurring charges relating to the debt refinancing and organisational changes
• Increased gross dividend of € 0.96 per share recommended by Board of Directors